DaVita (NYSE:DVA – Get Free Report) is anticipated to issue its quarterly earnings data after the market closes on Tuesday, February 11th. Analysts expect the company to announce earnings of $2.14 per share and revenue of $3.27 billion for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.
DaVita Price Performance
Shares of DVA opened at $176.93 on Tuesday. The business has a 50-day moving average of $159.91 and a 200-day moving average of $155.57. DaVita has a 1 year low of $108.76 and a 1 year high of $179.60. The company has a market capitalization of $14.51 billion, a price-to-earnings ratio of 19.09, a price-to-earnings-growth ratio of 0.86 and a beta of 0.93. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on DVA. Truist Financial increased their price objective on shares of DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research report on Monday, October 7th. Barclays raised their target price on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $161.80.
About DaVita
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Articles
- Five stocks we like better than DaVita
- Upcoming IPO Stock Lockup Period, Explained
- How to Invest in Small Cap Stocks
- What is Forex and How Does it Work?
- These Are the Dividend Stocks Insiders Bought in January
- What is the Hang Seng index?
- How the ‘No Buy’ Trend of 2025 Is Boosting These 3 Stocks
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.
